title: Quest for new biomarkers in atherosclerosis.
abstract: The Cho and Baldan labs focus their efforts on novel pathways that control atherogenesis. MIF (Macrophage migration inhibitory factor) recruits macrophages to atherosclerotic lesions and activates the production of matrix proteinases, which in turn destabilize atherosclerotic plaques. On the other hand, miR-33 coordinates the expression of several sterol transporters essential for high-density lipoprotein metabolism and bile secretion. Thus, both MIF and miR-33 are promising therapeutic targets to manage patients at risk of developing atherosclerosis.
authors.affiliation: Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, USA. ycho9@slu.edu
authors.forename: Yoonsang
authors.initials: Y
authors.lastname: Cho
authors.forename: Angel
authors.initials: A
authors.lastname: Baldán
mesh_terms: D050197:Atherosclerosis / Q000235:genetics / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D006801:Humans; D008263:Macrophage Migration-Inhibitory Factors / Q000378:metabolism*; D035683:MicroRNAs / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; C550416:MIRN33a microRNA, human; D008263:Macrophage Migration-Inhibitory Factors; D035683:MicroRNAs